{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:56:15Z","timestamp":1792684575802,"version":"4.5.0"},"reference-count":37,"publisher":"Scientific Scholar","content-domain":{"domain":["cytojournal.com"],"crossmark-restriction":true},"short-container-title":["Cytojournal"],"abstract":"\nObjective<\/jats:title>\nPancreatic cancer is the cancer type with the highest mortality rate worldwide, and despite advances in treatment, molecular biomarkers are needed for both early diagnosis for developing targeted therapies and improving survival rates in this challenging malignancy. In our study, the contributions of programmed death-ligand 1 (PD-L1) expression to the determination of pancreatic cancer subtypes and patient prognosis and its impact on survival were investigated.<\/jats:p>\n<\/jats:sec>\n\nMaterial and Methods<\/jats:title>\nParaffin-embedded tissues from 92 patients diagnosed with pancreatic cancer were included in this study. Tumor-infiltrating lymphocytes (TILs) and lymphocytes in the stromal area within the tumor borders were scored as stromal TILs; lymphocytes in tumor islands were scored as intratumoral TILs. Staining in each area was scored as a percentage, and staining with a score of 5 or more in tumor and immune cells for PD-L1 was scored as positive.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nAfter staining, a score of 5 or more with tPD-L1 staining was used to identify one patient as having micropapillary adenocarcinoma, three patients as having ductal adenocarcinoma, and four patients as having signet ring cell carcinoma. When the clinical parameters and outcomes were compared, a statistically significant difference was found between the histopathologic type of signet ring cell carcinoma and poor differentiation and positivity of PD-L1 expression (P<\/jats:italic> < 0.05). Survival was significantly influenced by tumor location, histopathological subtype, degree of differentiation, PD-L1 expression, and tumor size, with tumor size being the most critical factor (P<\/jats:italic> < 0.05).<\/jats:p>\n<\/jats:sec>\n\nConclusion<\/jats:title>\nOur findings suggest that PD-L1 positivity is notably prevalent in signet ring cell carcinoma of the pancreas and is strongly associated with poor survival outcomes. Given these results, further studies with larger patient cohorts are warranted to validate these observations and explore potential therapeutic implications.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/cytojournal_2_2025","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T06:54:08Z","timestamp":1746600848000},"page":"47","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is programmed death-ligand 1 positivity a predictor of poor survival in patients with different histological subtypes of pancreatic cancer?"],"prefix":"10.25259","volume":"22","author":[{"given":"Ceren","family":"Canbey","sequence":"first","affiliation":[{"name":"Department of Medicine Pathology, Bagcilar Research and Training Hospital, Istanbul, T\u00fcrkiye"},{"name":"Department of Molecular Oncology, Hamidiye Health Sciences Institute, University of Health Sciences, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena","family":"\u015een","sequence":"additional","affiliation":[{"name":"Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senem","family":"Karabulut","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, Hamidiye Health Sciences Institute, University of Health Sciences, Istanbul, T\u00fcrkiye"},{"name":"Department of Clinic Oncology, Oncology Institute, Istanbul University, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevhide Bilgen","family":"\u00d6zcan","sequence":"additional","affiliation":[{"name":"Department of Medicine Pathology, Bagcilar Research and Training Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Pa\u015fao\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medicine Pathology, Bagcilar Research and Training Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eren","family":"Altun","sequence":"additional","affiliation":[{"name":"Department of Medicine Pathology, Bagcilar Research and Training Hospital, Istanbul, T\u00fcrkiye"},{"name":"Department of Molecular Oncology, Hamidiye Health Sciences Institute, University of Health Sciences, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha Yusuf","family":"Kuzan","sequence":"additional","affiliation":[{"name":"Sancaktepe Martyr Prof Dr \u0130lhan Varank Research and Training Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikret","family":"Ezberci","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, Hamidiye Health Sciences Institute, University of Health Sciences, Istanbul, T\u00fcrkiye"},{"name":"Department of General Surgery, Umraniye Education and Research Hospital, University of Health Sciences, Istanbul, T\u00fcrkiye,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"10.25259\/Cytojournal_2_2025\/ref-1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.25259\/Cytojournal_2_2025\/ref-2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21772","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.25259\/Cytojournal_2_2025\/ref-3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.6004\/jadpro.2020.11.2.1","article-title":"The American cancer society's facts and figures: 2020 edition","volume":"11","author":"Viale","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"10.25259\/Cytojournal_2_2025\/ref-4","doi-asserted-by":"publisher","first-page":"102228","DOI":"10.1016\/j.canep.2022.102228","article-title":"Has the cancer-related death trend been changing in T\u00fcrkiye? An evaluation of the period between 2009 and 2019","volume":"80","author":"Teker","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"10.25259\/Cytojournal_2_2025\/ref-5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann Surg"},{"key":"10.25259\/Cytojournal_2_2025\/ref-6","doi-asserted-by":"publisher","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","article-title":"Pancreatic cancer: A review of current treatment and novel therapies","volume":"36","author":"Kolbeinsson","year":"2023","journal-title":"J Invest Surg"},{"key":"10.25259\/Cytojournal_2_2025\/ref-7","doi-asserted-by":"publisher","first-page":"LBA4002","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA4002","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial","volume":"36","author":"Van Tienhoven","year":"2018","journal-title":"Am Soc Clin Oncol"},{"key":"10.25259\/Cytojournal_2_2025\/ref-8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"10.25259\/Cytojournal_2_2025\/ref-9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"10.25259\/Cytojournal_2_2025\/ref-10","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J Cancer"},{"key":"10.25259\/Cytojournal_2_2025\/ref-11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.15386\/mpr-2116","article-title":"PD-1\/PD-L1 expression in pancreatic cancer and its implication in novel therapies","volume":"94","author":"Mucileanu","year":"2021","journal-title":"Med Pharm Rep"},{"key":"10.25259\/Cytojournal_2_2025\/ref-12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.canlet.2008.03.056","article-title":"Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer","volume":"268","author":"Loos","year":"2008","journal-title":"Cancer Lett"},{"key":"10.25259\/Cytojournal_2_2025\/ref-13","doi-asserted-by":"publisher","first-page":"71198","DOI":"10.18632\/oncotarget.11685","article-title":"Prognostic value of PDL1 expression in pancreatic cancer","volume":"7","author":"Birnbaum","year":"2016","journal-title":"Oncotarget"},{"key":"10.25259\/Cytojournal_2_2025\/ref-14","doi-asserted-by":"publisher","first-page":"e14006","DOI":"10.1097\/MD.0000000000014006","article-title":"Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis","volume":"98","author":"Hu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.25259\/Cytojournal_2_2025\/ref-15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.25259\/Cytojournal_2_2025\/ref-16","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"2","key":"10.25259\/Cytojournal_2_2025\/ref-17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"10.25259\/Cytojournal_2_2025\/ref-18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.5146\/tjpath.2021.01545","article-title":"Prognostic and predictive significance of PD-L1 expression in non-small cell lung cancer patients: A single-center experience","volume":"37","author":"Arak","year":"2021","journal-title":"Turk Patoloji Derg"},{"key":"10.25259\/Cytojournal_2_2025\/ref-19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.25259\/Cytojournal_2_2025\/ref-20","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.25259\/Cytojournal_2_2025\/ref-21","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00268-010-0448-x","article-title":"Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma","volume":"34","author":"Wang","year":"2010","journal-title":"World J Surg"},{"key":"10.25259\/Cytojournal_2_2025\/ref-22","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.5732\/cjc.009.10245","article-title":"Expression of B7-H1 protein in human pancreatic carcinoma tissues and its clinical significance","volume":"28","author":"Chen","year":"2009","journal-title":"Ai Zheng"},{"key":"10.25259\/Cytojournal_2_2025\/ref-23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00432-008-0364-8","article-title":"B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression","volume":"134","author":"Geng","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.25259\/Cytojournal_2_2025\/ref-24","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.25259\/Cytojournal_2_2025\/ref-25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J Immunother"},{"key":"10.25259\/Cytojournal_2_2025\/ref-26","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.25259\/Cytojournal_2_2025\/ref-27","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.25259\/Cytojournal_2_2025\/ref-28","doi-asserted-by":"publisher","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","article-title":"Dynamics of the immune reaction to pancreatic cancer from inception to invasion","volume":"67","author":"Clark","year":"2007","journal-title":"Cancer Res"},{"key":"10.25259\/Cytojournal_2_2025\/ref-29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s12885-022-09639-5","article-title":"Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.25259\/Cytojournal_2_2025\/ref-30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13000-017-0678-4","article-title":"PD-L1 in pancreatic ductal adenocarcinoma: A retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay","volume":"13","author":"Liang","year":"2018","journal-title":"Diagn Pathol"},{"key":"10.25259\/Cytojournal_2_2025\/ref-31","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/ccr3.2475","article-title":"Primary signet ring cell carcinoma of the pancreatic head: A case report","volume":"7","author":"Alexander","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.25259\/Cytojournal_2_2025\/ref-32","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1097\/COC.0000000000000447","article-title":"The impact of epidemiological factors and treatment interventions on survival in patients with signet ring cell carcinoma of the pancreas","volume":"41","author":"Patel","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.25259\/Cytojournal_2_2025\/ref-33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/pancan.2020.0013","article-title":"Primary pancreatic signet ring cell carcinoma: A case report and review of the literature","volume":"7","author":"Campbell","year":"2021","journal-title":"J Pancreat Cancer"},{"key":"10.25259\/Cytojournal_2_2025\/ref-34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12957-021-02478-x","article-title":"Prognosis and survival analysis of patients with pancreatic cancer: Retrospective experience of a single institution","volume":"20","author":"Li","year":"2022","journal-title":"World J Surg Oncol"},{"key":"10.25259\/Cytojournal_2_2025\/ref-35","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in pancreatic cancer: Making cold tumors hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.25259\/Cytojournal_2_2025\/ref-36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.hoc.2018.12.005","article-title":"Prognostic and predictive immunohistochemistry-based biomarkers in cancer and immunotherapy","volume":"33","author":"Rizk","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.25259\/Cytojournal_2_2025\/ref-37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/antib10010004","article-title":"Antibody identification for antigen detection in formalin-fixed paraffin-embedded tissue using phage display and naive libraries","volume":"10","author":"Mairaville","year":"2021","journal-title":"Antibodies (Basel)"}],"container-title":["Cytojournal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cytojournal.com\/is-programmed-death-ligand-1-positivity-a-predictor-of-poor-survival-in-patients-with-different-histological-subtypes-of-pancreatic-cancer\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cytojournal.com\/is-programmed-death-ligand-1-positivity-a-predictor-of-poor-survival-in-patients-with-different-histological-subtypes-of-pancreatic-cancer\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T06:54:49Z","timestamp":1746600889000},"score":1,"resource":{"primary":{"URL":"https:\/\/cytojournal.com\/is-programmed-death-ligand-1-positivity-a-predictor-of-poor-survival-in-patients-with-different-histological-subtypes-of-pancreatic-cancer\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":37,"alternative-id":["10.25259\/Cytojournal_2_2025"],"URL":"https:\/\/doi.org\/10.25259\/cytojournal_2_2025","relation":{},"ISSN":["1742-6413","0974-5963"],"issn-type":[{"value":"1742-6413","type":"electronic"},{"value":"0974-5963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"article-number":"47"}}